Work

Safety and exploratory efficacy of bosutinib in amyotrophic lateral sclerosis: a phase 2 trial using external controls

Year: 2026
Type: article
Abstract: Background Bosutinib, a selective Src/c-Abl inhibitor approved for the treatment of chronic myelogenous leukemia (CML), was identified as a molecularly targeted therapeutic candidate for amyotrophic lateral sclerosis (ALS) through induced pluripotent stem cell-based drug repurposing. To evaluate its safety and tolerability and explore its efficacy in ALS, an exploratory, multicenter, open-label phase 2 clinical trial was conducted. Methods This study included a 12-week observation period and a 24-week treatment period enrolling patients diagnosed with ALS within 2 years of symptom onset. Eligible patients were centrally allocated (1:1) to receive oral bosutinib at either 200 mg/day or 300 mg/day for 24 weeks. In lieu of a placebo control arm, efficacy was assessed using two external control datasets: placebo data of the edaravone Study MCI186-19 and registry data from the multicenter ALS cohort study, JaCALS, with outcomes evaluated by the total ALS Functional Rating Scale-Revised (ALSFRS-R). Results Between April 2022 and January 2024, 33 participants were screened, and 26 received bosutinib. Of these, 22 completed the 24-week treatment period and 4 discontinued treatment, primarily because of adverse events, with hepatic toxicity being the most common reason for discontinuation. No new safety signals specific to patients with ALS were identified. As a primary endpoint, the mean change from baseline in ALSFRS-R score at week 24 showed a smaller reduction in both dose groups compared with the placebo group in MCI186-19. The exploratory JaCALS comparison suggested a potential clinical signal of bosutinib. Exploratory biomarker analyses showed a decrease in plasma neurofilament light chain levels after treatment. Conclusions This early-phase study provides safety and tolerability data and exploratory efficacy findings for bosutinib in ALS. It also illustrates both the potential utility and limitations of external controls in a rare, rapidly progressive disease. Trial registration This trial was registered with ClinicalTrials.gov (NCT04744532) on February 9, 2021.
Source: BMC Medicine
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,190
OpenAlex ID: W7226692644
FWCI:
Cites:
Cited by:
Related to: 10